ANDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2015
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Novartis is clinical pharmacology pyridostigmine bromide tablets inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. First approved in 2015.
Drug data last refreshed 18h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pyridostigmine bromide tablets inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin ), but differs from it in certain…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Novartis
Worked on PYRIDOSTIGMINE BROMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.